These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1844 related items for PubMed ID: 16550520

  • 1. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS, Liu DS, Dai CW, Li RJ.
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [Abstract] [Full Text] [Related]

  • 2. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
    Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, Reddanna P.
    Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
    [Abstract] [Full Text] [Related]

  • 3. [Cytotoxic activities of Celecoxib on leukemic cells and the synergistic effects of Celecoxib with Imatinib thereupon].
    Li RJ, Gong FJ, Zhang GS.
    Zhonghua Yi Xue Za Zhi; 2006 May 30; 86(20):1417-20. PubMed ID: 16796927
    [Abstract] [Full Text] [Related]

  • 4. [Effect of celecoxib on enhancing the chemotherapic sensitivity of hydroxyurea to K562 cells and its mechanism].
    Liu DS, Zhang GS.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Oct 30; 29(5):495-9. PubMed ID: 16137030
    [Abstract] [Full Text] [Related]

  • 5. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW, Chong SY, Kim JY, Eom JI, Jeung HK, Maeng HY, Lee ST, Min YH.
    Clin Cancer Res; 2003 Oct 15; 9(13):5018-27. PubMed ID: 14581377
    [Abstract] [Full Text] [Related]

  • 6. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP, Auberger P.
    Oncogene; 2007 Apr 12; 26(17):2445-58. PubMed ID: 17043649
    [Abstract] [Full Text] [Related]

  • 7. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens.
    Swamy MV, Cooma I, Reddy BS, Rao CV.
    Int J Oncol; 2002 Apr 12; 20(4):753-9. PubMed ID: 11894121
    [Abstract] [Full Text] [Related]

  • 8. Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation.
    Peng HL, Zhang GS, Liu JH, Gong FJ, Li RJ.
    Ann Hematol; 2008 Feb 12; 87(2):121-9. PubMed ID: 17999062
    [Abstract] [Full Text] [Related]

  • 9. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
    Liu B, Shi ZL, Feng J, Tao HM.
    Cell Biol Int; 2008 May 12; 32(5):494-501. PubMed ID: 18078766
    [Abstract] [Full Text] [Related]

  • 10. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.
    Chandramohan Reddy T, Bharat Reddy D, Aparna A, Arunasree KM, Gupta G, Achari C, Reddy GV, Lakshmipathi V, Subramanyam A, Reddanna P.
    Toxicol In Vitro; 2012 Apr 12; 26(3):396-405. PubMed ID: 22245431
    [Abstract] [Full Text] [Related]

  • 11. Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro.
    Subhashini J, Mahipal SV, Reddanna P.
    Cancer Lett; 2005 Jun 16; 224(1):31-43. PubMed ID: 15911099
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
    Cui W, Yu CH, Hu KQ.
    Clin Cancer Res; 2005 Nov 15; 11(22):8213-21. PubMed ID: 16299255
    [Abstract] [Full Text] [Related]

  • 13. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
    Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, Marian B, Lichtenberg D, Arber N.
    Clin Cancer Res; 2005 Sep 15; 11(18):6738-44. PubMed ID: 16166455
    [Abstract] [Full Text] [Related]

  • 14. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S.
    Cancer Res; 2003 May 01; 63(9):2118-26. PubMed ID: 12727828
    [Abstract] [Full Text] [Related]

  • 15. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC, Zisterer DM.
    Biochem Pharmacol; 2009 Feb 01; 77(3):310-21. PubMed ID: 19014913
    [Abstract] [Full Text] [Related]

  • 16. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
    Lavallard VJ, Pradelli LA, Paul A, Bénéteau M, Jacquel A, Auberger P, Ricci JE.
    Cancer Res; 2009 Apr 01; 69(7):3013-20. PubMed ID: 19318579
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.
    Oncogene; 2002 Dec 12; 21(57):8804-16. PubMed ID: 12483533
    [Abstract] [Full Text] [Related]

  • 18. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
    Liu X, Yue P, Zhou Z, Khuri FR, Sun SY.
    J Natl Cancer Inst; 2004 Dec 01; 96(23):1769-80. PubMed ID: 15572759
    [Abstract] [Full Text] [Related]

  • 19. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
    Brieger A, Boehrer S, Schaaf S, Nowak D, Ruthardt M, Kim SZ, Atadja P, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.
    Biochem Pharmacol; 2004 Jul 01; 68(1):85-93. PubMed ID: 15183120
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, Nürnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 93.